Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390915 | 0.85 | DDB1 (0.53) | DDB1CRBNDRD2HRH4ALDH1A1 | |
| SCHEMBL15219423 | 0.82 | DDB1 (0.54) | DDB1CRBNDRD2HRH3ALDH1A1 | |
| SCHEMBL12424287 | 0.81 | DDB1 (0.49) | DDB1CRBNDRD2HRH3ALDH1A1 | |
| SCHEMBL2629310 | 0.80 | KMT2A (0.53) | DDB1CRBNDRD2ALDH1A1KCNH2 | |
| SCHEMBL15084326 | 0.79 | LMNA (0.56) | DDB1CRBNDRD2HRH3HRH4 | |
| SCHEMBL31010286 | 0.79 | HRH3 (0.42) | HRH3HRH4ALDH1A1KCNH2KDM4E | |
| SCHEMBL12384832 | 0.77 | DDB1 (0.46) | DDB1CRBNDRD2ALDH1A1KCNH2 | |
| SCHEMBL19250974 | 0.77 | ACHE (0.47) | DDB1CRBNDRD2HRH3KDM4E | |
| SCHEMBL15081958 | 0.76 | DDB1 (0.39) | DDB1CRBNDRD2 | |
| SCHEMBL18932731 | 0.76 | DDB1 (0.45) | DDB1CRBNDRD2ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | DDB1 212/4885CRBN 128/4885DRD2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.